
Rhenium Obisbemeda Shows No DLTs and Improves Survival in Recurrent Glioma
CancerNetwork® spoke with Andrew Brenner, MD, PhD, in the wake of the publication of results from the single-arm, phase 1/2 ReSPECT-GBM trial (NCT01906385) evaluating rhenium obisbemeda in patients with recurrent glioma. The median overall survival (OS …